57 results about "Terminal protein" patented technology

The present invention relates to a composition for preventing and treating dementia and memory impairment, which contains minocycline as active ingredient. The composition of the present invention has an effect of inhibiting brain cell death and memory impairment, which are induced by amyloid beta-protein and C-terminal protein. Thus, the composition of the present invention is useful for the prevention and treatment of various dementias, including Alzheimer's disease, and the impairment of learning and memory and cognitive function.

The present invention provides deleted adenovirus vectors. The inventive adenovirus vectors carry one or more deletions in the IVa2, 100K, polymerase and / or preterminal protein sequences of the adenovirus genome. The adenoviruses may additionally contain other deletions, mutations or other modifications as well. In particular preferred embodiments, the adenovirus genome is multiply deleted, i.e., carries two or more deletions therein. The deleted adenoviruses of the invention are “propagation-defective” in that the virus cannot replicate and produce new virions in the absence of complementing function(s). Preferred adenovirus vectors of the invention carry a heterologous nucleotide sequence encoding a protein or peptide associated with a metabolic disorder, more preferably a protein or peptide associated with a lysosomal or glycogen storage disease, most preferably, a lysosomal acid α-glucosidase. Further provided are methods for producing the inventive deleted adenovirus vectors. Further provided are methods of administering the deleted adenovirus vectors to a cell in vitro or in vivo.

A helper dependent adenoviral vector system is provided. The subject helper dependent adenoviral vector system is made up of: (1) a “gutless” adenoviral vector that include cis-acting human stuffer DNA that provides for in vivo long term, high level expression of a coding sequence present on the vector; (2) an adenoviral helper vector that is characterized by having an adenoviral genome region flanked by recombinase recognition sites, where the helper vectors further include a non-mammalian endonuclease recognition site positioned outside of the adenoviral genome region; and (3) a mammalian cell that expresses the corresponding recombinase and endonuclease, as well as the adenoviral preterminal and polymerase proteins. Also provided are methods of using the subject systems to produce virions having the subject helper dependent adenoviral vectors encapsulated in an adenoviral capsid. In addition, kits for use in practicing the subject methods are provided.

The invention discloses a stichopus japonicas BPI gene, an encoded protein, a cloning method of the stichopus japonicas BPI gene, and a method for constructing a recombinant stichopus japonicas BPI genetically engineered bacterium. The stichopus japonicas BPI gene is characterized in that a stichopus japonicas BPI gene sequence is as shown in SEQ ID NO.1; the cloning method comprises the step of designing a nested primer of RACE according to an expressed sequence tag EST sequence which is homologous to the BPI gene; a full-length gene is expanded by employing an RACE technique; a stichopus japonicas BPI protein sequence is as shown in SEQ ID NO.2; an N-terminal protein structure domain sequence is as shown in SEQ ID NO.3; an N-terminal structure domain of the stichopus japonicas BPI protein is amplified by employing primers which respectively comprise BamH I sites and Not I sites; the cloned target gene is inserted into a vector to obtain recombinant plasmids; and the recombinant plasmids are subjected to induced expression, and purification and renaturation, so as to obtain the genetically engineered bacterium. The stichopus japonicas BPI gene has the advantage of having obvious sterilization effect on vibrio parahaemolyticus, vibrio harveyi and micrococcus luteus.

A method of amplifying a template DNA molecule comprising incubating the template DNA molecule in a reaction mixture comprising a DNA polymerase and at least one accessory protein at a constant temperature to produce amplified product, wherein production of amplified product does not require exogenously-added oligonucleotide primers and the template DNA molecule does not have have terminal protein covalently bound to either 5′ end.

The present invention relates to an antifungal protein gene and cDNA sequence thereof, which is obtained by mining the whole genome sequences of Monascus pilosus BCRC 38072 and the unigene database. The gene can encode an antifungal protein MAFP1. A purified protein obtained from M. pilosus culture broth having molecular weight of about 7 kDa is identified as MAFP1 by N-terminal protein sequencing and comparative analysis. The purified MAFP1 protein can inhibit the growth of pathogens such as Paecilomyces variotii BCRC 33174 and Helminthosporium panici BCRC 35004. In addition, it is found by PCR test that the gene of this antifungal protein exists in other Monascus species such as M. Barkeri, M. floridanus, M. lunisporas, M. pilosus, M. ruber and the like. It is also been proved that the mafp1 gene and cDNA thereof in four Monascus strains, M. pilosus (BCRC 38072, BCRC 38093 and BCRC 31502) and M. ruber BCRC 31533, have the same DNA sequences.

The present invention relates to methods and compositions for the production of viral vectors. In particular, the present invention provides methods and compositions for faster, higher titer and higher purity production of viral vectors (e.g. adenoviral vectors). In some embodiments, the present invention provides gutted and helper viruses with identical or similar termini. In other embodiments, the present invention provides terminal protein linked adenoviral DNA. In certain embodiments, the present invention provides template extended adenoviral DNA.

The present invention discloses a preparation method and an application of cryptosporidium protein kinase 660 C-terminal protein. The preparation method comprises the following steps: S1, using amplification primers shown in SEQ ID NO:1-2 to conduct PCR amplification reaction to obtain a Cp 660 C gene segment; S2, carrying out double enzyme digestion on the Cp 660 C gene fragment and a prokaryoticexpression plasmid and conducting connection to obtain a Cp 660 C recombinant plasmid; S3, transferring the Cp 660 C recombinant plasmid into an expression host bacterium and picking a positive clonebacterium; S4, carrying out amplification culture on the positive clone bacterium until a growth logarithmic phase and carrying out induced expression; S5, carrying out refrigerated centrifugation onbacterial liquid after the induced expression, collecting bacterium body, discarding supernatant, washing the bacterium body, carrying out re-suspension, adding a protease inhibitor, carrying out icebath ultrasonic lysis on the bacterium body to obtain a lysate, then carrying out low-temperature centrifugation to obtain supernatant, and conducting filtering with a filter membrane; and S6, takingthe filtered supernatant in the step 5, purifying the supernatant through a Ni column, eluting the supernatant, and collecting a target protein. The method can obtain the recombinant protein with high purity and high antigen specificity, and the purified protein can be further used for analyzing and researching functionality of the cryptosporidium protein.

The present invention relates to an antifungal protein gene and cDNA sequence thereof, which is obtained by mining the whole genome sequences of Monascus pilosus BCRC 38072 and the unigene database. The gene can encode an antifungal protein MAFP1. A purified protein obtained from M. pilosus culture broth having molecular weight of about 7 kDa is identified as MAFP1 by N-terminal protein sequencing and comparative analysis. The purified MAFP1 protein can inhibit the growth of pathogens such as Paecilomyces variotii BCRC 33174 and Helminthosporium panici BCRC 35004. In addition, it is found by PCR test that the gene of this antifungal protein exists in other Monascus species such as M. Barkeri, M. floridanus, M. lunisporas, M. pilosus, M. ruber and the like. It is also been proved that the mafp1 gene and cDNA thereof in four Monascus strains, M. pilosus (BCRC 38072, BCRC 38093 and BCRC 31502) and M. ruber BCRC 31533, have the same DNA sequences.

The invention relates to methods for generating a recombinant adenovirus comprising a nucleotide sequence encoding a heterologous gene of interest for use as a vaccine comprising the steps of inserting the heterologous gene of interest into the adenovirus genome by recombining terminal protein complexed adenovirus genomic DNA (TPC-Ad gDNA) with a polynucleotide comprising a nucleotide sequence encoding the gene of interest and having 5' and 3' ends that are homologous to the insertion site sequence of the adenovirus genomic DNA in an in vitro recombination reaction, transfecting cells growing in individual vessels with a dilution of the in vitro recombination reaction mixture from (i) such that a number of such individual vessels contain a single cell that is infected by a recombinant adenovirus comprising the nucleotide sequence encoding the heterologous gene of interest, and identifying those individual vessels in which a single cell has been infected by the recombinant adenovirus comprising the nucleotide sequence encoding the heterologous gene of interest. Suitably said TPC-Ad gDNA comprises serotype-matched terminal protein and adenovirus genome, and said gene of interest codes for a single epitope, a string of epitopes, a segment of an antigen or a complete antigen protein. The invention also relates to recombinant adenoviruses and compositions made using these methods.

The present invention relates to the technical field of molecular biology, in particular to an adjustable luciferase segmented fusion protein, its preparation method and application. The fusion protein includes luciferase N-terminal protein, flexible peptide segment 1, MBP protein, Active valve, flexible peptide segment 2 and luciferase C-terminal protein; wherein, the luciferase N-terminal protein and luciferase C-terminal protein together form luciferase; the active valve is a section of 4-8 hydrophobic short Peptide Amino Acids. Through the short peptide chain amino acid sequence as the "active valve" and the specific cleavage enzyme as the "valve key", a new type of fluorescent complementary protein switching mode is realized, which can be used to evaluate the dynamic interaction of other proteins such as ligands Binding to a substrate, interactions that create new binding sites, protein-protein interactions that deactivate proteins, protein-protein interactions that alter the substrate specificity of a protein.

The present invention relates to the process of preparing target ribonuclease for curing hepatitis B virus infection. By means of molecular biological measures, it is constituted fusion protein of neurotoxin hEDN and HBV polymerase end protein structural domain DNAPTP or core protein originated from human eosinophil. The fusino protein, that is the said target ribonuclease, may be used in treating huma hepatitis B virus infection via gene therapy or protein medicine mode. Experiment shows that the target ribonuclease can reduce in vitro HBSAg for 46-59 % and inhibit obviously the duplicatino of hepatitis B virus. Available gene therapy or protein medicine mode may be refered to for its specific administratino way or mode.

The invention discloses a buildup method of an HPV gene yeast in vitro translating system. The improved yeast in vitro translating system built up by the method of the invention is particularly applicable to in vitro expression of coat protein of human papilloma virus (HPV), providing a convenient and rapid method for researching the coat protein expression system of the HPV. The system is also applicable to in vitro expression of other eukaryotic proteins at the same time. The buildup of the in vitro translating system of the invention provides an effective tool for the research of VLP forming and DNA package after terminal protein expression of the HPV and is hopeful to assist the research of HPV prevention and therapeutic vaccine. The method of the invention can also be used for preparing lysate of various yeast mutants researching the various factors that influence the protein translation after the transcription of eukaryotic mRNA and the reciprocity system of related molecular.